DEA looking for STOOL PIGEON

New DEA, AR National Guard Illegal Marijuana Growth Tipline

http://www.fox16.com/news/local-news/new-dea-ar-national-guard-illegal-marijuana-growth-tipline/742762612

NORTH LITTLE ROCK, Ark. – Law enforcement is cracking down on marijuana. Now, they are asking for your help to do so. 
 
The DEA says it’s using specialized equipment to get the drug out of Arkansas. 
 
Even though medical marijuana will be legal in Arkansas, there are certain rules on how to have it or grow it. It’s also against federal law. 
 
That’s why this summer the DEA, the Arkansas National Guard, and others will be looking for illegal growth operations. 
 
A special Arkansas National Guard helicopter is expected to get a lot of use this summer. It’s what the National Guard and law enforcement agencies across the state use to have eyes in the sky. They are looking specifically for marijuana. 
 
The Guard’s counterdrug coordinator says each summer they partner with the DEA and other agencies to eradicate illegal weed growth. 
 
“Usually they hover around 500 foot when they looking for marijuana plants,” said the counterdrug coordinator. 
 
“When you have a helicopter it changes the game and it makes your missions a great deal safer,” said Arkansas DEA assistant special agent in-charge Matthew Barden.
 
Barden says having help from the Guard makes the mission much safer. 
 
“Marijuana is still a money making venture, it’s a money making drug, it’s a money making crop so people guard those crops many times,” said Barden. 
 
This year they are doing something a bit different. They are branching out and asking for help. 
 
“Human intelligence is the greatest thing law enforcement has going for us,” said Barden. 
 
“If we have any information to narrow the scope down to where marijuana might be through getting information from other people, that’s key to us,” said the counterdrug coordinator. 
 
They have set up a tip line where people who might know where it’s being grown can call. Helping the teams up above get illegal drugs out of the ground. 
 
The hotline to call is 1-800-LEEF-U-C-0 (1-800-533-3820) 
 
If the DEA is able to get the marijuana plants and possibly charge someone you can get a reward for calling in. 

CRPS, chronic pain and suicide

HelpCRPS, chronic pain and suicide

www.blbchronicpain.co.uk/news/crps-chronic-pain-suicide/

 

This is not an easy topic to write about, but its a really important one. Please be aware that this article contains discussion of suicide and self harm.

Ill start bluntly: CRPS is colloquially known as the suicide disease. To most sufferers, that probably doesnt come as much of a shock; CRPS is the worst pain condition known to man, according to the McGill Pain Index. Its more painful than childbirth, than amputation of a finger; CRPS is as bad as it gets. If youre new to the condition, that Index might help you understand that your suffering really is as bad as you think it is. No, youre not making it up, no, youre not exaggerating, and yes, you really do need and deserve all the help you can get.

CRPS normally begins after an injury, but occasionally it simply comes out of thin air. Whichever scenario applies, it is an arrival that derails your normal physical functioning; where there should be reducing or zero pain, the agony simply spirals further and further out of control. My own CRPS developed after a nasty but fairly simple injury that should have been largely healed after a few weeks in plaster.

CRPS affects your mind, too

There is no way that this terrible life-changing pain can occur without it affecting your mental state. Just none, and many CRPS patients will become clinically depressed. It used to be believed that, because so many sufferers were depressed, CRPS was more common in those already suffering from or pre-disposed to depression; that was until someone actually thought about the situation and realised that if you have hideous, life-destroying pain, well, then youre probably very likely to be deeply unhappy, arent you? Its now understood that of course most CRPS patients develop depression, simply because CRPS is such an awful condition to have.

And unfortunately, the sad reality of living with terrible pain that derails your life utterly is that some people cant live with it. I cant find any reliable statistics about how many people with CRPS commit suicide. Theres references everywhere, as if suicide and CRPS is some open secret that everyone knows about but no-one really investigates: that suicide is 900 times more common in sufferers, that 70% have attempted suicide, but nothing verifiable. What I will say is this: I think pretty much everyone I know with CRPS knows at least one person with the condition whos tried to hurt themselves. I think pretty much everyone I know with CRPS has thought about it at some stage. I know I have.

Ill take an important pause here: in this piece Ive written about what to do if youre feeling suicidal or having thoughts about harming yourself. If you feel that way, please go there now. Please. Youre not alone and you dont have to feel this way.

The death of Bryan Spece

Im writing this article now because I read about the very sad death of Bryan Spece on Pain News Network. Bryan was a chronic pain patient, being treated with opioid medication for ongoing back and carpal tunnel pain. He was under the care of Rodney Lutes, a physicians assistant, working from the Benefis Pain Management Centre in Montana in the US. Rodney had prescribed Bryan a regimen of 100 milligrams of oxycodone daily and, according to Lutes, he was doing very well on this prescription. Hed been on this medication for around three years. Friends, family, and Lutes state that thered never been any sign of depression during this period.

In March of this year, however, the picture changed. Benefis discharged Rodney Lutes for undisclosed reasons and his patients were transferred to other doctors within the clinic. For Bryan this was a death sentence.

Bryans oxycodone was drastically reduced by his new doctor. He was not doing well on this new prescription, according to a relative. He was having money issues with not being able to work as often because of the pain and with having his pain pills cut back. He was just very stressed, constantly, about it.

Tragically, Bryan was found dead at home from a gunshot wound on May 3rd. The police found several text messages on his phone. He was talking to his friends there in Lewistown, stating Come get my guns. Im in so much pain, I might do something stupid. Bryans loved ones have no doubt that this is what eventually happened.

After Lutes departure from Benefis, form letters were sent to all his patients stating that their new doctors would probably change their prescriptions and advising them to be aware that arguing or complaining about changes in your prescriptions will not alter your clinicians care plan. Another letter says verbal or written complaints to staff will not result in a change to your prescription. In other words, you have no choice, no voice, and no chance.

Tapering opioid medication

The Center for Disease Control discusses tapering of opioid medication with the headline Go Slow, advising a maximum taper of 10% of dose per week and no more than 10% per month for those whove been on opioids for a while, like Bryan. It advises careful monitoring of a patients mental state during a taper of medication, and emphasises the importance of offering psychological support.

Bryan Speces dose of oxycodone was reduced from 100 milligrams daily to just 30 milligrams. Thats a reduction of 70%. I cannot find ANY literature anywhere that condones or even suggests that such a drastic taper is appropriate. Its hard to view Bryans treatment by his new doctor as anything other than cruel and unusual. His family blame the Benefis clinic 100% for Bryans death.

The American war on painkillers

I have written before about Americas war on opioids and the ever more stringent guidelines that are being presented by various government bodies and politicians, seemingly in some competition to be seen as the hardest on drugs. I also wrote about my fear that wed count the impact of this policy in dead pain sufferers. The terrible, life-ending problem with this initiative is that it abandons the genuine chronic pain patient, the person, exactly like me, who is absolutely reliant on strong painkillers to live their life. These people are patients, not addicts; how dare anyone who signs the Hippocratic oath treat them with such callous and cruel indifference? Complaining about your new prescriptions wont change anything. Arguing will have no effect either. How far do we have to go to be heard? Will you listen to me if I put a gun to my head?

As I said previously, there is no doubt that chronic pain goes hand in hand with depression. Life-altering pain that takes everything you love from you will undoubtedly render the most optimistic person unhappy. During the early years of my CRPS, there were times when I was significantly depressed and I seriously wondered whether I could continue to live this way.

Coping strategies for chronic pain

The reality, though, is that by gaining the right support for me, those feelings passed. I love my life now, despite the CRPS, despite the constant pain that invades every single thought, every single second I have. A significant part of that support was psychological, enabling me to think differently about my new situation. Some of it was surgical, with my spinal cord stimulator making a big difference to my pain levels and functioning. Another important element was pain management techniques, including the month I spent learning mindfulness at St Thomas Hospital in London.

A big, important, undeniable, essential part, however, is my daily opioid pain medication. Without it, I could not cope. Without it, I dont know if Id be here today. Thats not over-dramatising, its simply the truth. If my pills were taken away tomorrow, like Bryans were, I dont know if I would be able to see a way forward through my haze of pain either.

It makes me mad as hell to know that we failed Bryan so badly that he couldnt see a way to continue living. And it is our failure; we, as a society, have allowed these guidelines to be put in place and weve allowed genuine patients to be treated this way. Imagine the outcry if we allowed chemotherapy to be stopped for cancer patients. So how can we be allowing this to happen?

#PatientsnotAddicts

It may feel like were powerless, but actually were not, not completely. If youre in the USA, then you can get involved with a group like Patients Not Addicts and theyll tell you how to lobby your politicians to protect these essential drugs for chronic pain patients. In the UK, were not yet experiencing the drive to curb opioid medications like in the US but I fear its coming. Ill continue to monitor the situation and will write about any developments.

I will end with a request: If you believe that pain patients are not addicts, if youre a chronic pain sufferer yourself, if you love someone with chronic pain, if youre simply someone who understands that no medication is necessarily bad as long as its used appropriately, then please speak up. Make your voice heard. It is needed more than ever right now. If we dont, then I fear Bryan will simply be one of the very first casualties of this callous policy. Dont let his death be in vain.

 

Wisconsin Senate passes bills targeting opioid abuse

Wisconsin Senate passes bills targeting opioid abuse

http://lacrossetribune.com/news/state-and-regional/wi/wisconsin-senate-passes-bills-targeting-opioid-abuse/article_e7228cc2-df0b-5bea-a89e-90592c13d547.html

MADISON, Wis. (AP) — The Wisconsin state Senate has approved a pair of bills designed to help fight drug abuse and addiction.

 

One bill the Senate passed on a voice vote Wednesday would allow emergency and involuntary commitment for drug addicts. Supporters say that would be a tool to help put someone on the road to recovery.

 

The other approved would ensure that someone who overdoses would be immune from probation or parole revocation if he or she enters a treatment program. Backers say the change would encourage people to call for help in an emergency. It passed 32-1 with Republican Sen. Steve Nass voting no. He says it goes too far in granting immunity.

Both measures were sponsored by Republican Rep. John Nygren, of Marinette. They now head to Gov. Scott Walker for his consideration.

Investigative reporter: wants to talk to US Veterans and family members of Veterans

Call for Participation:

I invite US Veterans and family members of Veterans to assist me in supporting an investigative reporter in mainstream media who is developing a story for television on the “other” side of the so-called opioid crisis. If you are willing to share your experience with being denied or arbitrarily tapered down on opioid medications that have been helpful for you in the past, then please send a contact email address and phone to lawhern@hotmail.com. You may also include a paragraph on how you have been personally affected by the CDC’s 2016 opioid prescription guidelines. Also of interest will be narratives from medical professionals who have been forced by VA policy to reduce or stop prescribing to their patients.

Be aware that there are no guarantees that this program will reach the public. The project must be developed and “sold” first. But this is at least a start.

This from Red Lawhern

Please participate

Cutting of pain management therapy.. turning a “maker” into a “taker”

I have chronic back pain and hereditary migraines. I had been taking fiornal w/ codeine when I lived in California. During my worst month I was at 120 pills. And I had been managing my pain with that drug for probably 26 years.

 I recently moved to Washington state and the pain management clinic dropped me to 5mg fioricet. This is completely insufficient. I am literally at risk of losing my job because I’m paralyzed with pain.

What can I do?

 

Fiorinal with Codiene has 30 mg of Codeine in each capsule… so using those “fussy math” opiate conversion table… this pt was getting morphine equivalents of 18 mg/day..

The only difference between Fiorinal and Fioricet is that the former has Aspirin in it and the latter has Acetaminophen (Tylenol) in it..

So this pain clinic changed this pt’s medication and basically dropping the (fairly low dose of) Codeine from the pt’s pain management.

Since he is employed and this pain clinic’s decisions – plan of treatment – causes him to lose his job… then that is monetary damages and some law firm may be willing to sue for monetary damages.

Apparently this pt has documentation was to what was working for him and this pain clinic has made a intentional decision to cut the Codeine out of his therapy and could cause the pt to lose his job.

Aspirin Bleeding Risk in Over 75s Higher Than Thought

Aspirin Bleeding Risk in Over 75s Higher Than Thought

http://www.medscape.com/viewarticle/881575

Taking aspirin for secondary prevention of stroke or myocardial infarction (MI) is associated with a higher than expected risk for disabling or fatal bleeding in people aged 75 years and older, a new observational study shows.

The authors suggest that all patients aged 75 years or older prescribed aspirin for secondary prevention should also be given a proton-pump inhibitor (PPI) to protect against gastrointestinal (GI) bleeding. 

The study was published online in The Lancet on June 13.

“We knew before that there was an increased risk of bleeding with aspirin in the elderly, but what we didn’t know was how high that risk was and the consequences of those bleeds,” senior author, Peter Rothwell, MD, John Radcliffe Hospital, University of Oxford, United Kingdom, explained to Medscape Medical News.

 “There has been a sense that antiplatelets prevent important ischemic events, such as stroke and MI, and while we knew there is an increased risk of bleeding, this was seen as bit of a nuisance and not equivalent to the ischemic events. But our data shows that actually the bleeding is more likely to be disabling than the strokes in this age group so really needs to be taken more seriously.”

Professor Rothwell notes that many of these bleeds are preventable with PPIs.     

“About half the bleeds in this study were GI bleeds and more than half of disabling or fatal bleeding were GI, and we know from previous studies that PPIs can prevent about 80% of GI bleeding caused by antiplatelet agents.” 

He pointed out that current guidelines advise that patients receiving long-term antiplatelet drugs should be co-prescribed a PPI if they are high risk for bleeding, but they don’t define “high risk.”

“Our data show that pretty much anyone 75 years of age or over should be categorized as high risk,” he said. “I think we could make a reasonable argument for everyone in this age group who is taking long-term antiplatelet therapy for secondary prevention of MI or stroke to be also prescribed a PPI.”

Is Aspirin Necessary Long Term?

But the question has also been raised as to whether long-term aspirin should be prescribed for these patients in the first place.

Commenting for Medscape Medical News on the new study, John Cleland, MD, Imperial College London, United Kingdom, who has long been an aspirin skeptic, suggested that these new data provide further evidence against giving aspirin long term after a stroke or MI.

 “There is no compelling evidence that aspirin continued for greater than 28 days after an event is beneficial,” Dr Cleland said. “The antiplatelet meta-analysis is based on long-term trials that were neutral and done more than 40 years ago before the era of modern medicine. ISIS-2, the only truly positive study, only treated post-MI for 28 days.”

“Doctors should know they are using guesswork rather than evidence-based medicine if they give aspirin for longer than 28 days,” he added. “We need to stop prescribing useless polypharmacy. And PPIs can have risks too, such as increased risk of Clostridium.”

 Responding to this, Professor Rothwell said, “It’s a very difficult question on whether aspirin should be given to older patients long term as all the studies have been done in younger patients. There isn’t much trial information on this age group, so we can’t, hand on heart, say there is a clear-cut benefit long term in the elderly.”   

“But we don’t want to throw the baby out with the bath water,” he added. “I think we need to conform to the guidelines, which recommend that everyone should have an antiplatelet drug after an MI or stroke to reduce recurrent ischemic events, even the elderly. However, we need to do more to prevent bleeding with these drugs.”

 He acknowledged that there is a question about how long aspirin should be given. “We could perhaps do a trial where aspirin is withdrawn after a year or so in those patients without active cardiovascular disease. That is a valid research question.”
 Oxford Vascular Study

For the study, the researchers analyzed bleeding events in 3166 patients (50% age 75 years or older) treated with antiplatelet drugs (mainly aspirin based) after a first transient ischemic attack, ischemic stroke, or MI in the Oxford Vascular Study, a population-based study of the incidence and outcome of all acute vascular events in a population of 92,728 individuals, irrespective of age, registered at nine general practices in Oxfordshire, United Kingdom.

 Patients were started on antiplatelets from 2002 to 2012, with follow-up until 2013. Around 30% were receiving some sort of gastric protection (PPI or histamine-2 antagonist).
 Results showed that 405 patients had first bleeding events (218 gastrointestinal, 45 intracranial, 142 other) during 13,509 patient-years of follow-up. The average annual risk for bleeding was 3.36%; the risk for major bleeding was 1.46%.
 Risk of nonmajor bleeding was unrelated to age, but the annual risk for major bleeding increased steeply above age 70 years, reaching 4.1% at age 85 years or older, with similar patterns for both life-threatening and fatal bleeding. This finding reflects high risks of upper GI and intracranial bleeding at older ages.
 The hazard ratio (HR) for major bleeding in patients aged 75 years or older was 3.10, and the HR for fatal bleeding in this age group was 5.53 (compared to those younger than age 75 years).
 The same was true of major upper GI bleeds (≥75 years: HR, 4.13), and the risk was particularly increased for disabling or fatal GI bleeding (HR, 10.26) in this age group.
 There were 489 nonfatal and 208 fatal ischemic vascular events during follow-up. The ratio of major bleeds to ischemic events increased sharply with age: 0.20 in patients younger than 75 years, 0.32 for those aged 75 to 84 years, and 0.46 for those aged 85 years or older.
 The authors further point out that the risk for major bleeds estimated to be attributable to antiplatelet treatment was similar to the risk for ischemic events estimated to have been prevented in the group 85 years of age or older.  
 They report that in the 75-years-or-older group, major upper GI bleeds were mostly disabling or fatal (45 of 73 patients [62%]) and were more likely to be disabling and fatal than recurrent ischemic strokes (101 of 213 patients [45%]).     
 Disabling or fatal GI bleeds also outnumbered disabling or fatal intracerebral hemorrhage (45 vs 18) in this age group.
 The researchers tried to assess the benefit that routine PPI treatment may have in this population by using data from a meta-analysis of randomized trials of PPIs vs placebo in patients taking antiplatelet drugs (predominantly aspirin), in which PPI use reduced upper gastrointestinal bleeding by 74%.

Using this estimate, they estimate that the number need to treat (NNT) with PPIs to prevent one major upper GI bleed at 5 years’ follow-up is 80 for patients younger than 65 years, 75 for patients aged 65 to 74 years, 23 for patients aged 75 to 84 years, and 21 for patients aged 85 years or older.

 The NNT with PPIs to prevent one disabling or fatal upper GI bleed at 5 years’ follow-up also decreased with age, from 338 for patients younger than 65 years to 25 for patients aged 85 years or older.
 In a comment accompanying the Lancet paper, Hans-Christoph Diener, MD, University Duisburg-Essen, Essen, Germany, says that the benefit–risk association of long-term antiplatelet therapy should be regularly evaluated in patients older than 75 years, as is done with oral anticoagulants in patients with atrial fibrillation. 
 He agrees with the researchers that the study supports the use of PPIs in patients aged 75 years or older receiving antiplatelet therapy.
 Dr Diener points out that PPIs are underused in patients receiving antiplatelet therapy, perhaps because the consequences of upper GI bleeds were underestimated in elderly patients who were treated with aspirin. 
 He also notes that a study published last year suggested a correlation between PPI use and dementia “was reported widely in the media and created a lot of confusion and angst” but was small and underpowered.
 Professor Rothwell noted that PPIs prevent only GI bleeding, and there would still be other bleeds, the most serious of which are intracerebral hemorrhage (ICH). “This is an issue that needs to be considered, and we need to focus on patients’ blood pressure to reduce the ICH risk. But on the whole non-GI bleeding is less preventable.
 “Our recommendation is that all patients 75 years of age or over discharged after a stroke or MI on aspirin should be co-prescribed a PPI, and this should be continued long-term.”  
 At present, patients are often prescribed aspirin at discharge, with hospital physicians thinking the family doctor may follow up with a PPI, but that doesn’t necessarily happen, he said.   
 “Also, while we don’t feel that all patients over 75 currently taking antiplatelet agents should be recalled at this point in order to start a PPI, I do think it is reasonable that when they do go to see their family doctor they are advised to start a PPI,” he said. “Our data show that while the risk of bleeding is highest in the first couple of years it is still significantly elevated over the longer term.”  
 The researchers estimate about half the population older than age 75 is taking aspirin (60% of the US population vs 40% of the UK population in this age group). The current study included patients taking aspirin for secondary prevention after having had a stroke, transient ischemic attack, or MI. Professor Rothwell estimates that these patients make up about two thirds of those taking aspirin, with the other third taking aspirin for primary prevention of cardiovascular disease.
 “I think our results can be applied to the secondary prevention population immediately, but it is not clear whether the primary prevention population taking aspirin also need to be on a PPI, as they do seem to have a lower risk of bleeding.”

 

Lawsuit challenges Kentucky’s ban on using marijuana for medical purposes

 

Lawsuit challenges Kentucky’s ban on using marijuana for medical purposes

http://www.kentucky.com/news/politics-government/article156091284.html

Several Kentuckians who say they get relief from medical marijuana filed a lawsuit Wednesday to challenge the state’s criminal ban on the drug, arguing that cannabis is naturally effective and does not have the addictive dangers of opioid painkillers.

In their suit, filed in Franklin Circuit Court, Dan Seum Jr., 59, and Amy Stalker, 37, both of Jefferson County, and Danny Belcher, 69, of Bath County say that over half of Americans now are permitted by the states where they live to use marijuana for chronic pain and other ailments. But in Kentucky, depending on how much of the drug they possess, marijuana users risk felony or misdemeanor convictions that could put them behind bars.

The plaintiffs are asking the court to decriminalize marijuana possession and trafficking for themselves “insofar as they seek to use cannabis for valid medicinal purposes.” Under Kentucky law, having eight or more ounces of marijuana in one’s possession is considered sufficient evidence of intent to sell it to others.

“It becomes cruel when you have a solution that works and is helping people in other states, but if people use it here, they’re criminals,” Stalker said in a recent interview.

Stalker said she has a long history of health problems due to irritable bowel syndrome and bipolar disorder and the powerful pharmaceutical drugs that were prescribed to her to treat those conditions. In recent years, Stalker said, she has successfully treated herself with a combination of cannabis, amino acids and other natural substances that are gentler to her body.

 

Stalker still carries the medical marijuana patient’s license the state of Colorado issued her four years ago when she lived there and a prescription written by her doctor for the strain called Bubble Hash. However, both pieces of paper became worthless the day she moved back to Kentucky to care for her ailing mother.

“When I’ve talked to legislators in Frankfort about this, their advice was for me to move away again, to go live in a state where it’s legal,” she said. “But I grew up here. I love it here. My family is here. Is that really a choice I should have to make to stay healthy?”

It’s “getting appalling” that Kentucky leaders have consistently ignored their constituents’ pleas to allow marijuana, “especially when the Bourbon Trail is such a fabulous thing to boast about,” Seum said.

Amy Stalker says she had more control over her own health when she lived in Colorado, where marijuana can be legally prescribed as medicine. Stalker now lives in Kentucky, where medical use of marijuana is banned.

jcheves@herald-leader.com

The plaintiffs are represented by Dan Canon, a Louisville civil-rights attorney who was part of the legal team that defeated Kentucky’s ban on same-sex marriage in 2015.

The suit names Gov. Matt Bevin, a Republican, and Attorney General Andy Beshear, a Democrat, as defendants. It claims that Kentucky’s medical marijuana ban violates the plaintiffs’ rights under the Kentucky Constitution to privacy and to be free of the “absolute and arbitrary power” of the state over their “lives, liberty and property.”

“The exercise of the commonwealth’s police powers to criminalize cannabis for medicinal purposes is an unjust result of the broad prohibition against cannabis and has wrought an unjust hardship for Mr. Seum, Ms. Stalker, Mr. Belcher and thousands of other medical cannabis users in Kentucky who were left with the unconscionable choice to either live in permanent pain from their illnesses, risk taking highly addictive and proven deadly opioids or benzodiazepines, or live as criminals for their use of cannabis to treat their illnesses,” the suit claims.

Smoked or ingested, cannabis has been used as medicine for most of recorded history. It was a legal remedy in the United States as recently as the mid-20th century. In 1970, however, as the war on drugs began, the U.S. government classified marijuana as a Schedule 1 controlled substance, the designation intended for drugs — like heroin — that are supposed to have a high potential for addiction and no medical value.

Since 1996, 29 states and the District of Columbia have authorized the medical use of marijuana within their borders, including West Virginia, Ohio and Illinois. While the federal government still considers the drug to be illegal nationwide, Congress voted in May to give the U.S. Justice Department no money to prosecute medical marijuana cases in states where such use has been permitted.

Kentucky is not one of those states. The Kentucky General Assembly — where plaintiff Seum’s father is a longtime Republican state senator — has rejected several medical marijuana bills in recent years. The one it did approve, Senate Bill 124 in 2014, was very narrowly written: It let certain pediatric seizure patients use an oil derived from hemp and marijuana under carefully controlled conditions.

The state officials named as defendants in the suit appear split over the subject. Bevin has said on several occasions that he would support legalization of marijuana for medical use, although not for recreational use.

“The devil is in the details,” Bevin said during a radio interview in February. “I am not against the idea of medical marijuana if prescribed like other drugs, if administered in the same way that we would other pharmaceutical drugs. I think it would be appropriate in many respects. It has absolute medicinal value. But again, that’s a function of (a bill) making its way to me. I don’t get to do that executively, it would have to be a bill.”

In contrast, Beshear said during his 2015 attorney general campaign that he would not consider even limited legalization unless the U.S. Food and Drug Administration authorized cannabis as a medicine.

On Wednesday, spokespeople for the two elected officials said they have not had adequate opportunity to review the lawsuit.

In their suit, the plaintiffs explain the myriad ways that cannabis has helped them.

Seum, for example, was a football coach at Farnsley Middle School in Louisville from 2008 to 2012. Worsening back pain led him to try spinal fusion surgery, followed by an OxyContin prescription. He soon realized, to his horror, that he had become addicted to OxyContin, affecting his cognitive and motor skills and interfering with his coaching job. So he asked his doctor to begin reducing the dosage.

Seum started using cannabis to manage his pain and nausea from OxyContin withdrawal. Since then, several doctors have refused to help Seum with his continuing back problems unless he agreed to stop using marijuana. He has self-medicated with cannabis since 2014.

But possessing the drug is illegal, with penalties that can vary depending on the attitude of local law enforcement. A Jefferson County police officer who caught him with “a tiny fraction of an amount” gave him a $67 citation for the drug; a prosecutor in Grayson County sent him to jail for two days for roughly the same amount.

“It was gonna be four (days) and they made it two, the judge did, and I had to do two days in jail,” Seum said in a recent interview. “I couldn’t have my meds. I had to sleep on a cold, steel rack with four rods in my back. It was terrible, terrible. But there was no getting out of it.”

Belcher served in the Vietnam War during the late 1960s as a combat infantry sergeant. As a result of his combat service, Belcher suffers from post-traumatic stress disorder, alcoholism and a compression fracture in his spine, according to the suit.

The U.S. Department of Veterans Affairs put Belcher on a number of powerful pharmaceutical drugs, including Valium, Librium and Tylenol 3 with codeine. The medicines “left me feeling fuzzy-headed, and they were eating up my insides,” Belcher said recently. By occasionally smoking marijuana at home, he said, an option the VA refused to discuss with him, he has been able to discontinue the use of the prescribed medicines, stop drinking alcohol and manage his health problems.

“It’s not a daily thing. If I need it, I’ve got my pipe,” Belcher said.

“I know veterans who are drugged out of their minds on 25 or 30 pills for all sorts of stuff, approved by the VA. They drug the daylights out of us Vietnam vets because they don’t know what else to do with us,” Belcher said. “And then I’ve got friends in the states where (marijuana) is legal, and they’re getting the relief that they need. These aren’t a bunch of stoners using it recreationally. They use it when they’re in pain, and that’s it, and it works for them.”

Dr. Andrew Kolodny: wants all opiates taken off the market ?

The FDA Is Going After an Opioid Painkiller for the First Time

www.motherjones.com/politics/2017/06/the-fda-is-going-after-an-opioid-painkiller-for-the-first-time/

Last Thursday, for the first time in history, the Food and Drug Administration asked a pharmaceutical company to take an opioid painkiller off the market. The agency found that the benefits of the medication, Opana ER, were outweighed by its risks: It is frequently snorted and injected, and linked to HIV outbreaks, the spread of hepatitis C, and a blood clotting disorder called thrombotic microangiopathy.

“We are facing an opioid epidemic—a public health crisis, and we must take all necessary steps to reduce the scope of opioid misuse and abuse,” said FDA Commissioner Dr. Scott Gottlieb in a statement. “We will continue to take regulatory steps when we see situations where an opioid product’s risks outweigh its benefits, not only for its intended patient population but also in regard to its potential for misuse and abuse,” said Gottlieb.

The FDA’s request may indicate that the commissioner, accused of cozy relationships with pharmaceutical companies, is taking a tough stance on painkiller prescribing, which has laid the foundation for today’s soaring overdose epidemic. “I am pleased, but not because I think that this one move by itself will have much impact,” says Dr. Andrew Kolodny, who researches opioid policy at Brandeis University and directs Physicians for Responsible Opioid Prescribing.

“I’m hopeful that this signals a change at FDA—and that Opana might be just the first opioid that they’ll consider taking off the market. It’s too soon to tell.”

Opana ER (for extended release) was created by Endo Pharmaceuticals and approved by the FDA in 2006. After finding that drug users crushed and snorted the drug, taking in 12 hours worth of medication instantaneously, Endo introduced a reformulated version in 2012, which had a hard shell that Endo claimed made the drug more difficult to abuse. This decision may have been motivated by more than just public safety—as NPR noted, Endo faced loss of patent protection without a reformulation. But the FDA found that the reformulation made abuse more likely than the former version: instead of snorting it, users took to injecting it—leading to a cluster of thrombotic microangiopathy deaths in Tennessee in 2012 and Indiana’s HIV outbreak in 2014 and 2015.

The FDA’s decision doesn’t necessarily indicate that Opana ER is more abusable than other opioid painkillers still on the market, but rather that it is riskier than the previous (now generic) version. In fact, Opana ER is chemically similar to a number of other painkillers, notes Kolodny. High dosage painkiller pills in particular are easily abused: Without tolerance to opioids, experimenting with one 80-milligram OxyContin pill or Subsys prescription fentanyl spray could cause an overdose. Critics worry that even “abuse-deterrent” versions of painkillers, which typically are harder to crush or dissolve and are marketed as a safe alternative to other opioids, are still abusable. “Abuse-deterrent formulations are no less addictive and no less effective and they are mostly going to take our eye off the ball,” says Dr. Caleb Alexander, co-director of Johns Hopkins University’s Center for Drug Safety and Effectiveness. If you are dealing with opioid addiction, you can look into Residential Addiction Care Facilities for help.

Whether or not Endo will comply remains to be seen; the company is “evaluating the full range of potential options as we determine the appropriate path forward,” according to a prepared statement. Since last Thursday’s announcement, its stock price has plummeted by nearly 20 percent. If Endo doesn’t pull its product, the FDA “intends to take steps to formally require its removal by withdrawing approval,” according to a press release.

He stated, because it is his pharmacy he can do what he wants !

This pharmacist told my  nurse I could pick up my pain medication  a day earlier,which is today 6-14-17 that he insisted telling me I cannot pick it up for 2 days ,He stated because it is his store he can do what he wants ! he lied to her of our talk . His family are very old in this town and well known . so of course folks will believe him , he has always been a spoiled brat , age now of 48 , yes that is beside the point .Others have had similar complaints of Jody’s professionalism .

This is another good example of why pts need to audio/video recording of all interactions with healthcare providers – or in this case a healthcare denier – 

IMO.. if a healthcare provider will intentionally throw a pt into cold turkey withdrawal… there is little reason to believe that they are not also capable of lying to cover their ass about what happened or was said/promised.

In today’s environment… the healthcare provider will probably pull the “addict card” to support and defend the lie they are putting forth as to what happened… and the pt won’t stand a chance of prevailing.

While this Pharmacist is correct that “it is his pharmacy“… but his license and the license to operate a pharmacy belongs to the state and the state can take both of them away, if it is found that the way that he operates could harm the health and safety of the general public

 

Is this what happens when addiction is treated as a chronic disease ?

The case for prescription heroin

Vancouver gives heroin to drug users suffering from addiction — and it works.

https://www.vox.com/policy-and-politics/2017/6/12/15301458/canada-prescription-heroin-opioid-addiction

VANCOUVER, British Columbia — The Providence Crosstown Clinic is decorated with posters espousing the sort of medical advice you might expect at any other doctor’s office: Cover your cough, wash your hands, don’t use antibiotics to treat the flu, and ask staff if you need any help.

In the main treatment room, a familiar smell of rubbing alcohol lingers in the air — the kind of scent I associate with getting a vaccine shot. At Crosstown, the smell is the remnants of the medicine that 130 to 150 patients inject themselves with multiple times a day at the clinic.

Except the injection here isn’t a vaccine. It’s medical-grade heroin.

A clinic where patients use heroin may sound shocking and irresponsible, particularly now, as a deadly and devastating opioid epidemic ravages North America. But this approach is meant to treat the victims of that epidemic.

The idea is this: If some people are going to use heroin no matter what, it’s better to give them a safe source of the stuff and a safe place to inject it, rather than letting them pick it up on the street — laced with who knows what — and possibly overdose without medical supervision. Patients can not only avoid death by overdose but otherwise go about their lives without stealing or committing other crimes to obtain heroin.

And it isn’t some wild-eyed theory; the scientific research almost unanimously backs it up, and Crosstown’s own experience shows it can make a difference in drug users’ lives.

“People are forced into the illicit stream of opioids because they can’t get legal access to meet their opioid needs,” said Scott MacDonald, Crosstown’s head physician. “So they will access whatever is available and least expensive.”

Crosstown represents an international move toward providing a full spectrum of care for people who are addicted to drugs. It isn’t a first-line defense against opioid addiction, and it’s not going to solve the crisis by itself. But for a fraction of opioid users suffering from addiction (maybe about 10 to 15 percent), other treatments won’t produce good results, almost certainly leading users to relapse — and possibly overdose and die.

To combat this cycle, Crosstown offers these opioid users medical-grade heroin (called “diacetylmorphine”). Under supervision, nurses are at the ready with the overdose antidote naloxone and oxygen tanks in case of an emergency. These patients are the people for whom other treatments have failed. It’s a last resort. And it works.

Since 2011, the clinic has seen about 200 patients. None of them, MacDonald said, have died under the clinic’s supervision. In fact, as far as he can tell, no one has died at any prescription heroin facility due to an overdose — not in Canada, Switzerland, Germany, or the Netherlands.

“So relatively safe,” I said.

“Yes,” MacDonald said. “Well, not even relatively. It’s safe.”

Heroin-assisted treatment has been used in the UK since 1926. But it’s gained more international attention in the past couple of decades thanks to Switzerland’s embrace of it in the 1990s. Twenty-one clinics there (and a prison program) now deploy the treatment. Due to the opioid epidemic, the approach is now getting more attention in the US — MacDonald even testified in front of Congress last year.

But Crosstown is still the only clinic of its kind in North America. And despite its success, the concept of a full spectrum of addiction care, including heroin-assisted treatment, isn’t even close to reality in the US — which is experiencing its deadliest drug overdose crisis in history and which, report after report has found, often doesn’t offer even the bare minimum of addiction care. A clinic like Crosstown, though, provides a beacon for how the country can move forward as it tackles its opioid epidemic.

Crosstown’s lifesaving work

A line of about a dozen patients quietly formed at the door to the injection room at Crosstown. One of them approached MacDonald as I stood to the side. “Thank you for saving my life,” he said.

As MacDonald and I shuffled through patients to his office, I asked him how often this sort of thing happens. “Daily,” he said.

Crosstown is run like a standard doctor’s office. Outside the injection room, clients patiently sit in waiting rooms, chatting about their families, getting and keeping a job, and, of course, their drug treatment. It’s a typical clinical setting, aside from the people injecting heroin just a few steps away.

When it’s their turn, patients will line up, go into the injection room, get the drug prescribed to them, and inject it. The room is surrounded by mirrors that make it impossible to hide from your own image — and, helpfully for staff, make it hard for patients to do anything without getting caught, like smuggle drugs out of the room.

When they’re done, the patients move on with their days — to the kind of school, work, and family that just about any other person can expect to have.

The clinic has been open since 2011, residing in a downtown building that used to be a bank (as the old-timey vault in Crosstown’s basement shows). Although the concept of heroin-assisted treatment has been around for decades, the recent opioid crisis has led Canada — and particularly British Columbia — to step up the work, with Prime Minister Justin Trudeau enacting rules in 2016 to potentially expand the treatment.

Scott MacDonald, head physician at the Crosstown Clinic in Vancouver, Canada.

In 2015, the latest year with data, drug overdoses killed more than 52,000 people in the US, and more than 33,000 of those deaths were linked to opioids. The total drug overdoses dwarf car crashes (more than 38,000 deaths in 2015), gun deaths (more than 36,000 that year), and even HIV/AIDS at its peak (more than 43,000 in 1995).

Canada and particularly Vancouver haven’t been spared. As I heard repeatedly while visiting the city in April, there were nearly 1,000 drug overdose deaths in British Columbia in 2016 — an unprecedented death toll in a province of around 4.7 million people. Vancouver’s city officials say the clinic is part of their comprehensive approach to the growing drug crisis.

“For people who are in care with us, we’ve not had a single opioid overdose death,” MacDonald said. “We’re like a bubble immune to this — at least, knock on wood, today.”

Even within the context of the opioid epidemic, recent events had made approaches like Crosstown’s more urgent. City officials estimate that more than 80 percent of the heroin bought in the streets is now contaminated with deadlier, more potent opioids like fentanyl and its analogs. On the street, someone might unknowingly shoot up these drugs, which their tolerance can’t handle, and overdose. But in a clinical setting like Crosstown, doctors and nurses can ensure the heroin they supply is not laced with these chemicals.

As Maryland-based drug policy experts Bryce Pardo and Peter Reuter wrote in a recent editorial in the Baltimore Sun, “Heroin-assisted therapy addresses the immediate overdose threat posed by fentanyl — something naloxone attempts to do after the fact. Prescribed heroin use in a clinical and supervised setting ensures that users are not consuming fentanyl and that staff are on hand should something go wrong.”

Vancouver offers a glimpse at how this would work in North America. And so far, it’s working very well.

A patient’s lifelong struggle — until now

One Crosstown patient, John Pinkney, can trace his drug use back to the age of 6, when he was first prescribed Ritalin. By his 20s, he was using heroin and other street drugs. Now in his late 50s, he says his life is in a much better place. He has a part-time job. He brags about owning a television and furniture — the kinds of things others might take for granted, but were hard-fought for someone struggling with drug addiction.

“I have a two-bedroom apartment,” Pinkney said. “I have things. I got my TV and my pet and living room furniture and bedroom furniture. You know, it’s like I got my life back.”

None of this, he said, would be possible for him without the Crosstown Clinic.

Pinkney laughed nervously as he retold his story. He was an orphan, passed around from home to home until at around 8 years old he ended up with “a middle-class, government family” in Edmonton, Canada. His mom was abusive — chasing him around the house, beating him, and at one point even threatening him with a knife.

Around age 14, Pinkney ran away from home — “too much violence,” he said — and was cut off from his Ritalin prescription. Despite attempts to buy it off the street, the lack of a steady prescription, he said, made him feel like he was “missing something.” In his 20s, he filled that void with illicit substances like heroin.

John Pinkney, a patient at the Crosstown Clinic.

He eventually ended up in prison for several years, following a series of robberies for money to buy drugs.

Pinkney heard of the Crosstown program a few years ago from his brother-in-law, who is also a heroin user. Pinkney — along with his wife, who also used heroin — decided to check it out. It changed his life.

“Within the first month and a half, I was able to go back to school,” Pinkney said. “Just by the mere fact of coming here, I didn’t have to worry about where my money was going. I didn’t have to go spend all my money on drugs.”

This proved a massive change for Pinkney. Previously, he estimates he and his wife were spending $500 a day on drugs. To pay for that, his wife “worked the street,” and he, for some time, stole and scavenged trash cans and dumpsters (“binning”) for things to sell. When they became patients at Crosstown — which is covered by government-provided insurance — they both were able to stop doing illegal or unsafe work to buy drugs.

Pinkney now feels like his life is on track. He works a part-time job as a security guard at an apartment building, and he gets disability insurance. He also regularly talks to media about his experience, fashioning himself as an advocate for heroin-assisted treatment. Last year, he injected his prescription heroin in front of thousands of live viewers for the New York Times.

 

Above all, though, Pinkney is proud that his life is fairly normal now. That doesn’t mean the treatment is easy. He comes to the clinic three times a day for heroin — in the morning, in the afternoon, and at night. This is typical for more frequent heroin users and standard for the clinic. The drug’s effects wear off quickly, so patients need to go back to it multiple times a day to avoid withdrawal.

Yet even two or three visits a day may not be enough for some, so the clinic offers some patients a dose of methadone, an opioid often used in medication-assisted treatment, in their evening session so they can get through the night before their morning session.

For Pinkney, this busy schedule isn’t too much of a burden. And even if it were, the alternative — going back to hustling for drugs that might be laced with more lethal chemicals — is worse.

“When you look at the social consequences of that, it’s far superior going at this route than going the other route,” he said.

Before starting heroin-assisted treatment, Pinkney tried Alcoholics Anonymous and Narcotics Anonymous. He tried Christian-based treatment centers. Even methadone didn’t work for him. So he continued using heroin, even while on methadone.

After decades of struggles, Crosstown gave him a much-needed way out.

The research shows heroin-assisted treatment works

The idea of treating opioid addiction with opioids isn’t new. For years, doctors have prescribed the opioids methadone and buprenorphine to get users off more dangerous opioids like heroin and traditional painkillers. When taken as prescribed, methadone and buprenorphine eliminate someone’s cravings for opioids and withdrawal symptoms — to help avoid relapse — without producing the kind of euphoric high that heroin or more traditional painkillers can.

These drugs, used in medication-assisted treatment, are largely considered the best form of care for opioid addiction. The research on this point is, frankly, indisputable, with public health groups like the Centers for Disease Control and Prevention, the National Institute on Drug Abuse, and the World Health Organization all acknowledging methadone and buprenorphine’s medical value.

Medication-assisted treatments don’t work for everyone, though; up to 40 percent of opioid users don’t respond well to methadone or buprenorphine. Pinkney complained of bone aches on methadone, while MacDonald noted that some patients feel symptoms such as nausea, headaches, and fatigue. For others, even high doses of these drugs are simply ineffective.

“When treating any medical condition, no one substance will work for everybody,” MacDonald said. “Methadone and Suboxone [buprenorphine] are great treatments. They work for many people. But what are we going to offer those folks [they are] not working for, continue using illicit opioids, [and] are forced into crime in order to get the medication that they need?”

For some of these patients, heroin-assisted treatment can help.

Researchers credit Switzerland’s program with reductions in drug-related crimes and improvements in social functioning, such as stabilized housing and employment. Canadian studies also deemed heroin maintenance effective for treating heavy heroin users. A review of the research — which included randomized controlled trials from Switzerland, the Netherlands, Spain, Germany, Canada, and the UK — reached similar conclusions, noting sharp drops in street heroin use among people in treatment.

One of the Canadian studies, the results of a randomized controlled trial published in the New England Journal of Medicine, put the promise of heroin maintenance treatment this way:

In this trial, both diacetylmorphine [heroin] treatment and optimized methadone maintenance treatment resulted in high retention and response rates. Methadone, provided according to best-practice guidelines, should remain the treatment of choice for the majority of patients. However, there will continue to be a subgroup of patients who will not benefit even from optimized methadone maintenance. Prescribed, supervised use of diacetylmorphine appears to be a safe and effective adjunctive treatment for this severely affected population of patients who would otherwise remain outside the health care system.

As the study notes, the treatment is typically available as a kind of second, third, or last resort — for patients who just haven’t had success with other kinds of care.

“There are some people who are going to — no matter what — just continue to inject,” David Juurlink, a doctor who studies the opioid epidemic at the University of Toronto, told me. “These are people who are literally waiting to die if they don’t have access to a supervised consumption facility.”

The approach is not without detractors. The International Task Force on Strategic Drug Policy, for one, argues that programs like Vancouver’s “promote the false notion that there are safe or responsible ways to use drugs.” The group argues that this kind of program — and other harm reduction strategies — weakens the social stigma against drugs, leading more people to try and use these dangerous substances.

But the danger here isn’t whether someone is using drugs; most Americans, after all, use caffeine or alcohol regularly throughout their lives with few problems. Drug use transforms into addiction, according to the definition provided by the Diagnostic and Statistical Manual of Mental Disorders, when using drugs begins hurting someone’s function — by, for example, leading them to steal or commit other crimes to obtain heroin, or, in the worst case scenario, death.

The Providence Crosstown Clinic in Vancouver.
The Providence Crosstown Clinic in Vancouver.
German Lopez and Javier Zarracina/Vox

Heroin-assisted treatment relieves this problem: It gives patients a safe place to get their heroin without resorting to bad behaviors.

Still, experts and those involved in Crosstown emphasize it’s not a first-line treatment. For instance, MacDonald said Health Canada, which covers the care provided at Crosstown for some patients, requires a laundry list of qualifications for coverage: 18 years or older, at least five years of opioid use, regular illicit opioid use in the past year, current use of illicit opioids, physical or psychological complications as a result of opioid use, and previous attempts to get drug treatment, particularly medication-assisted treatment like methadone or buprenorphine.

So even if this treatment method spreads throughout North America, it’s never going to be a matter of just walking into the clinic and getting some heroin — as can happen at “medical” marijuana dispensaries in the US today.

Also, clinics like Crosstown aren’t just about supplying heroin; they offer a chance to link drug users to other forms of aid, including social workers, other health care and treatments, and, potentially, a plan to wean people off opioids altogether — although some patients will use heroin for years or life.

“With time, a third to half the people step down to oral options, like methadone, or to abstinence,” MacDonald said. “But we don’t arbitrarily say, ‘Okay, you’ve been with us for six months. It’s time to reduce your dose.’ There’s a study out of Belgium — they have injectable treatment there — that shows if you just arbitrarily stop people, they will go back to using illicit opioids.”

The US fails to provide full addiction care

In the US, more than 20 million Americans suffer from some form of drug addiction — about 8 percent of the adolescent and adult population. According to the surgeon general, “That number is similar to the number of people who suffer from diabetes, and more than 1.5 times the annual prevalence of all cancers combined (14 million).”

But there’s still so much we don’t know about how addiction works. We don’t even know why it afflicts some people but not others, and why some treatments work for certain individuals but not large segments of the population.

In this environment, experts argue, it’s best to provide a spectrum of options that can help all sorts of different patients with various kinds of individualized problems.

“It’s just like any other chronic disease,” Keith Ahamad, a clinical researcher at the University of British Columbia, told me. “We need a stepwise approach to managing patients. If you’re not able to engage and stabilize patients on less intensive treatment, then, like you do for other chronic conditions, you step them up to more intensive treatment modalities.”

Yet while Canada considers expanding heroin-assisted treatment, the US isn’t able to meet the medical needs of as many as 90 percent of patients with drug use disorders, based on the surgeon general’s 2016 addiction report, due to the high costs and low supply of adequate addiction care.

The treatment that does exist in America is often ineffective. Much of the focus in the US is on abstinence, which is potentially dangerous for opioids. If someone quits heroin cold turkey, they’re going to quickly lose the tolerance they developed over years of use. So if they relapse (which is expected in addiction medicine), they may overdose after they try the quantities of heroin they were used to before.

Dr. Scott MacDonald and patient John Pinkney at the Providence Crosstown Clinic in Vancouver.
Dr. Scott MacDonald and patient John Pinkney at the Providence Crosstown Clinic in Vancouver.
German Lopez and Javier Zarracina/Vox

But groups like the Drug Free America Foundation (which did not respond to multiple requests for comment) say that abstinence is necessary, arguing that anything short of it is simply masking and even enabling dangerous drug use. Addiction experts disagree with this view, but it’s prevalent in the US — sometimes with deadly results.

In 2013, Judge Frank Gulotta Jr. in New York ordered an opioid user arrested for drugs, Robert Lepolszki, off methadone treatment. In January 2014, Lepolszki died of a drug overdose at 28 years old — a direct result, Lepolszki’s parents say, of failing to get the medicine he needed. In his defense, Gulotta has continued to argue that methadone programs “are crutches — they are substitutes for drugs and drug cravings without enabling the participant to actually rid him or herself of the addiction.”

In the case of Lepolszki, methadone seemed key to saving his life. While this is one case, the idea that using methadone, buprenorphine, or other opioids for treatment is simply “replacing one drug with another” — without any consideration for the broader context of how the replacement drug is used — is a standard misconception in America.

Meanwhile, Vancouver’s government is moving forward with the full spectrum of care, including Crosstown. Chris Van Veen, the lead urban health planner for Vancouver, told me, “Unfortunately with addiction, there’s no silver bullet. Any treatment that we have doesn’t have very high success rates. Traditional abstinence treatments have incredibly low success rates.” That, he said, is why it’s important to let people “have access to as many treatment options as possible.”

This won’t stop all drug overdose deaths. British Columbia is still suffering from a very bad opioid crisis, even though it already does many of the things that experts think the US health care system should do in response to drug addiction — from heroin-assisted treatment to medication-assisted therapy to other kinds of prevention and rehabilitation. But adopting an approach like Vancouver’s would, experts say, at least help greatly reduce the death toll.

How one US city is trying to move forward

As the opioid epidemic surges, some US lawmakers are seriously looking at approaches like Vancouver’s.

Ithaca, New York, Mayor Svante Myrick is pushing for supervised injection facilities and considering heroin-assisted treatment as part of his comprehensive plan to deal with the opioid epidemic.

Several years ago, Myrick put together a 50-person committee to study how to solve the opioid crisis. He gave them just one condition: “We got a large drug problem. We’re not going to arrest our way out of it. So don’t come back and say we need more SWAT teams and police officers.” As part of the 25 proposals the committee put forward, the committee recommended building a supervised injection facility and studying heroin-assisted treatment.

So Myrick and Ithaca’s former police chief, John Barber, went to the Crosstown Clinic and a supervised injection facility, Insite, in Vancouver. Myrick was impressed, finding “that by providing the heroin, you cut down on street crime.”

But Myrick hasn’t been able to get a supervised injection facility — much less a heroin-assisted treatment clinic — off the ground. He blames that on hesitation from state lawmakers, who would need to change the law to let his plans move forward.

“We’re enacting the other 23 parts of our plan,” he said, listing more after-school programs and medication-assisted treatment among the other pieces. “But we’re really in limbo right now until we can get the votes out of the New York state legislature.”

After decades of a war on drugs fought mostly through the criminal justice system, getting US lawmakers to open up to alternative approaches — or even just widely accepted approaches like methadone and buprenorphine — is going to take a lot of time and patience.

“They still think it’s a way to condone drug use or encourage it. Which is madness,” Myrick said. “Anywhere you study it, it does the exact opposite: You get fewer deaths, fewer diseases, fewer people using.”